{"id":3846,"date":"2025-03-31T18:11:51","date_gmt":"2025-03-31T18:11:51","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/cladribine-txt\/"},"modified":"2025-03-31T18:11:51","modified_gmt":"2025-03-31T18:11:51","slug":"cladribine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/cladribine-txt\/","title":{"rendered":"Cladribine.txt"},"content":{"rendered":"

Cladribine<\/h1>\n

CLINICAL USE <\/H3>
\nAntineoplastic agent:Hairy cell leukaemia (HCL) Chronic lymphocytic leukaemia (CLL) in patients who have failed to respond to standard regimens

DOSE IN NORMAL RENAL FUNCTION <\/H3>Leustat:HCL: 0.09 mg\/kg (3.6 mg\/m 2) daily for 7 daysCLL: 0.12 mg\/kg (4.8 mg\/m 2) daily for 2 hours on days 1 to 5 of a 28 day cycleLitak:HCL: 0.14 mg\/kg\/day for 5 days by subcutaneous injectionor according to local protocol

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :285.7<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :20<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 18<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :9<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :3\u201322\/No data

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Use with caution.
  • 10 to 20 &nbsp &nbsp : Use with caution
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Use with caution

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsCaution when administering with any other immunosuppressive or myelosuppressive therapy

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>SC,

    IV infusion <\/H4>

    Rate of Administration <\/H4>24 hours or 2 hours depending on condition being treated

    Comments<\/H4>Add to 100\u2013500 mL of sodium chloride 0.9%

    OTHER INFORMATION <\/H4>Prodrug \u2013 activated by intracellular phosphorylation. The nucleotide that is formed accumulates in the cell and is incorporated into the DNA. Regular monitoring is recommended in renal failure Acute renal insufficiency has developed in some patients receiving high-dose . Inadequate data on dosing of patients with renal insufficiency therefore use according to clinical needStudy showed that
  • <10 <\/LI>% of dose is excreted in urine as metabolites and <20% as parent drug.
    \n","protected":false},"excerpt":{"rendered":"

    Cladribine CLINICAL USE Antineoplastic agent:Hairy cell leukaemia (HCL) Chronic lymphocytic<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3846","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3846"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3846\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}